Clinical Trial Update: Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder [Phase 2]

View source ↗

Summary

Phase 2 trial of durvalumab (Medi4736) for BCG-refractory urothelial carcinoma in situ of the bladder (terminated; results posted).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Carcinoma in Situ of the Bladder

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Carcinoma in Situ of Bladder, Bladder Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-06-11